摘要
目的:观察肿瘤标志物在非小细胞肺癌(NSCLC)后程超分割放疗同步化疗中的变化,评价以上肿瘤标志物的临床价值.方法:43例NSCLC患者均进行后程逐量加速超分割照射(LCEHART)同步两周期化疗,分别于治疗前以及治疗完成后3wk进行肿瘤特异性生长因子(TSGF)以及多肿瘤标志物蛋白芯片检测.结果:TSGF,Ft,CA125在治疗开始时的阳性率分别为67%,53%,55%,治疗后所观测指标中TSGF和CA125有显著性下降(P<0.05),尤其对于达CR的患者.在治疗有效的患者中,CA125阴性患者的近期生存期显著长于阳性患者.结论:NSCLC患者LCEHART同步NP方案化疗中,对于治疗有效患者,TSGF,CA125的下降与影像学资料具有一致性;并且CA125可以作为预后指标.
AIM： To observe the changes of TSGF, Ft and CA125 in non-small-cell lung cancer （NSCLC） treated by latecourse escalated hyperfractionated accelerated radiotherapy （LCEHART） combined with chemotherapy and to evaluate the clinical significance of the above tumor makers. METHODS： Forty-three NSCLC patients were treated by LCEHART combined with two-cycle chemotherapy, and TSGF and multi-tumor maker protein chip were detected before and 3 weeks after therapy. RESULTS： The positive rate of TSGF, Ft and CA125 was respectively 67%, 53% and 55% before the treatment. After treatment, significant decrease was observed in TSGF and CA125 （ P 〈 0.05 ） , especially in patients of complete response （CR）. Patients of CR and partial response （PR） with negative CA125 expression had longer recent survival time compared with the patients with positive expression （ P 〈 0.05 ）. CONCLUSION ： In NSCLC patients who are effectively treated by LCEHART combined with NP chemotherapy, the decrease of TSGF and CAi25 is consistent to the imaging changes. CA125 thus can be used as a prognosis index.
出处
《第四军医大学学报》
北大核心
2009年第16期1512-1514,共3页
Journal of the Fourth Military Medical University
基金
荆门市科技基金[荆科技2008(6号)/08S19]
关键词
肺肿瘤
肿瘤标记
生物学
蛋白芯片
放射疗法
药物疗法
lung neoplasms
tumor markers, biological
protein chip
radiotherapy
drug therapy
